[cmsms_row data_width=”boxed” data_padding_left=”3″ data_padding_right=”3″ data_color=”default” data_bg_position=”top center” data_bg_repeat=”no-repeat” data_bg_attachment=”scroll” data_bg_size=”cover” data_bg_parallax_ratio=”0.5″ data_padding_top=”0″ data_padding_bottom=”50″][cmsms_column data_width=”1/1″][cmsms_selected_products orderby=”date” order=”DESC” ids=”3256″ columns=”3″][/cmsms_column][/cmsms_row][cmsms_row][cmsms_column data_width=”1/1″][cmsms_text] Menopur 75mg inj
FERRING PHARMACEUTICALS LTD
GENERIC NAME : HMG
What is Menopur ?
MENOPUR (HP-hMG) is a highly purified human menopausal gonadotrophin containing a 1:1 ratio of FSH (follicle stimulating hormone) and LH (luteinizing hormone) bioactivity.
Menopur (also called human menopausal gonadotropin or hMG) is a hormonally active medication for the treatment of fertility disturbances. Frequently the plural is used as the medication is a mixture of gonadotropins. Menopur is extracted from the urine of postmenopausal women.
Why Menopur is Prescribed in IVF technique ?
• Anovulatory women: MENOPUR can be used to stimulate follicle
development in amenorrhoeic patients.
• Women undergoing superovulation within a medically assisted fertilisation programme: MENOPUR can be used to induce multiple follicular development in patients undergoing an assisted conception technique such as in-vitro fertilisation (IVF).
• Hypogonadotrophic hypogonadism in men: MENOPUR may be given in combination with human chorionic gonadotrophin (e.g. CHORAGON) for the stimulation of spermatogenesis.
How Menopur is Helpful ?
Menopur preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy. They can also be used in hypogonadal men to stimulate sperm production.
Human urinary-derived Menopur preparations are exposed to the theoretical risk of infection from menopausal donors of urine. Nevertheless, the failure to irrefutably demonstrate infectivity following intracerebral inoculation with urine from transmissible spongiform encephalopathy(TSE)-infected hosts suggests that the risk associated with products derived from urine is merely theoretical.
[/cmsms_text][/cmsms_column][/cmsms_row]